ERAS

Erasca, Inc.

2.12 USD
+0.01 (+0.24%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Erasca, Inc. stock is down -18.34% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 June’s closed higher than May. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
17 May 14:44 21 Jun, 2024 2.50 CALL 2400 108

About Erasca, Inc.

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia.